Tilapia-Head Chondroitin Sulfate Protects against Nonalcoholic Fatty Liver Disease via Modulating the Gut-Liver Axis in High-Fat-Diet-Fed C57BL/6 Mice.
Hui YuXiangzhou YiXia GaoJun JiZhongyuan LiuGuanghua XiaChuan LiXueying ZhangXuanri ShenPublished in: Foods (Basel, Switzerland) (2022)
We isolated and characterized tilapia-head chondroitin sulfate (TH-CS) and explored its biological activity and mechanisms of action as an oral supplement for nonalcoholic fatty liver disease (NAFLD) induced by a high-fat diet (HFD) in mice. The results showed that treatment with TH-CS for 8 weeks alleviated the development of NAFLD, as evidenced by the notable improvement in liver damage, blood lipid accumulation and insulin resistance (IR). Meanwhile, TH-CS treatment reduced the expression of proinflammatory cytokines and normalized oxidative stress. Additionally, the analysis of 16S rDNA sequencing revealed that TH-CS could restore gut microbiota balance and increase the relative abundance of short-chain fatty acid (SCFA)-producing bacteria. Furthermore, SCFAs produced by related bacteria can further improve lipid metabolism and IR by regulating lipid synthesis signals. In conclusion, TH-CS is an effective dietary supplement for the prevention of NAFLD, and may serve as a potential supplementary treatment for lipid-related metabolic syndrome.
Keyphrases
- high fat diet
- insulin resistance
- metabolic syndrome
- adipose tissue
- oxidative stress
- fatty acid
- high fat diet induced
- type diabetes
- poor prognosis
- skeletal muscle
- dna damage
- cardiovascular disease
- signaling pathway
- ischemia reperfusion injury
- single cell
- polycystic ovary syndrome
- climate change
- induced apoptosis
- binding protein
- wastewater treatment
- hyaluronic acid
- preterm birth